In contrast to IL-6 signaling, we found little evidence for an effect of serum IL-6 levels on risk of MS (OR = 0.71, 95% CI = 0.09-5.64, p = 0.75) (Figure 2, Supplementary Table 31 and Supplementary Figure 4). This evidence concerns the gene IL6 and myeloid sarcoma.